Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes


1University of Utah Huntsman Cancer Institute, Salt Lake City, UT; 2Mayo Clinic, Rochester, MS; 3University of Minnesota, Twin Cities of Minneapolis and Saint Paul, MN; 4University of Alabama Medicine, Birmingham, AL; 5Virginia Commonwealth University Health, Richmond, VA; 6The Ohio State University, Columbus, OH; 7University of Colorado Cancer Center, Aurora, CO; 8Roswell Park Comprehensive Cancer Center, Buffalo, NY; 9University of Oklahoma Health Sciences Center, Oklahoma City, OK; 10Tisch Cancer Institute at Mount Sinai, New York, NY; 11Karmanos Cancer Institute, Detroit, MI; 12University of Kentucky HealthCare, Lexington, KY; 13University of Iowa Hospitals and Clinics, Iowa City, IA and 14University of California, Irvine, CA, USA

*Current address: City of Hope Medical Center, Duarte, CA, USA

Correspondence: H. Shah
harsh.shah@hci.utah.edu

Received: January 19, 2023.
Accepted: April 19, 2023.
Early view: April 27, 2023.

https://doi.org/10.3324/haematol.2023.282780

©2023 Ferrata Storti Foundation
Published under a CC-BY license
Supplemental Figure 1: Time Independent Analysis for Progression Free Survival based on total cumulative dose